Akso Health (AHG) Cash & Equivalents (2017 - 2026)

Akso Health (AHG) has reported Cash & Equivalents for 10 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 99.89% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (down 99.89% YoY) and the FY2026 annual result came in at $200000.0, down 99.89% from the prior year.
• Cash & Equivalents fell to $200000.0 in Q1 2026 per AHG's latest filing, from $11.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for AHG reached as high as $176.2 million in Q1 2025 and fell as low as $4472.0 in Q1 2023.
• A 5-year average of $42.6 million and a median of $10.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 64635172.77% — and 2026, when it tumbled 99.89%.
• Year by year, Cash & Equivalents stood at $10.0 million in 2022, then decreased by 7.8% to $9.2 million in 2023, then jumped by 891.87% to $91.4 million in 2024, then plunged by 87.82% to $11.1 million in 2025, then sank by 98.2% to $200000.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $200000.0, $11.1 million, and $176.2 million for Q1 2026, Q3 2025, and Q1 2025 respectively.